Meta-analysis of randomized controlled trials of the effects of probiotics in Parkinson's disease

Chuanqi Chu,Leilei Yu,Yiwen Li,Hang Guo,Qixiao Zhai,Wei Chen,Fengwei Tian

DOI: https://doi.org/10.1039/d2fo03825k

2023-03-04

Abstract:Background: Patients with Parkinson's disease (PD) demonstrate intestinal dysbiosis and substantial gastrointestinal dysfunction. Preliminary evidence suggests that probiotics may have a positive effect on the motor and non-motor symptoms of PD. However, the effectiveness of probiotics in treating PD remains unclear. Therefore, a randomized controlled trial (RCT) was performed to examine the efficacy of oral probiotics in PD treatment. Methods: Systematic and manual screening of PubMed, Web of Science, Cochrane Library, EMBASE, Clinical Trials, and Google Scholar yielded nine RCTs that met the inclusion criteria. Meta-analyses have examined the effects of probiotics on motor and non-motor symptom parameters in RCTs. Inverse-variance random or fixed effects were used to pool data. The Grading of Recommendations Assessment, Development, and Evaluations was used to examine the quality of evidence for outcomes of the meta-analysis. Results: Nine eligible RCTs (N = 663) were included in this meta-analysis. In the meta-analysis, probiotic treatment significantly improved motor symptoms (UPDRS-III scores: standardized mean difference [SMD] = -0.28, 95% confidence interval [CI], -0.49 to -0.07, P = 0.009), the constipation and constipation-related quality of life (Bristol scores: SMD = 0.54; 95% CI, 0.35 to 0.73; P < 0.00001; Bowel Movement scores: SMD = 0.83; 95% CI, 0.59 to 1.07; P < 0.00001; CSBMs: SMD = 0.56; 95% CI, 0.30 to 0.82; P < 0.0001; PAC-QCL scores: SMD = -0.84; 95% CI, -1.08 to -0.60; P < 0.0001), anxiety and depression parameters (HAMA scores: SMD = -0.35; 95% CI, -0.60 to -0.10; P = 0.006; HADM-17 scores: SMD = -0.33; 95% CI, -0.59 to -0.08; P = 0.009). In addition, probiotic supplements significantly reduced the use of laxatives (SMD = -0.27; 95% CI, -0.53 to -0.01; P = 0.04) and increased GSH levels in the serum of PD patients (SMD = 0.52; 95% CI, 0.14 to 0.90; P = 0.007). The certainty of evidence was graded as low for UPDRS-III, PAC-QCL, CSBMs, HAMA, and HADM-17, moderate for Bristol and Bowel Movement scores.

biochemistry & molecular biology,food science & technology